Advanced pancreatic neuroendocrine tumors: how treatment is selected

Confirm the diagnosis beyond the word neuroendocrine

A pathology review should describe differentiation and grade, including the Ki-67 proliferation index where reported. These findings help distinguish a well-differentiated pancreatic NET from a poorly differentiated neuroendocrine carcinoma, which can behave differently and require a different treatment strategy.

Ask whether the available biopsy reflects the area now growing fastest. If the pace of disease has changed substantially, the team may discuss whether additional tissue would help. This is particularly relevant when a long-stable tumor develops a new, rapidly growing lesion.

Sources and references: [1]

Name the problem that needs treatment now

Treatment may be needed because tumors are growing, pressing on an organ, producing hormones or causing troublesome symptoms. Stable, low-volume disease raises a different question from rapidly enlarging liver metastases. A scan timeline helps establish the pace.

Hormone symptoms deserve their own plan. Some pancreatic NETs cause problems such as low blood glucose, severe diarrhea or excessive stomach acid. A medicine that controls hormone release may still be useful while another treatment addresses tumor growth. Ask which part of the plan targets each problem.

Sources and references: [1]

Somatostatin analogues and receptor assessment

Somatostatin analogues can help control symptoms from some functioning NETs and are used within selected tumor-control strategies. Their role depends on the tumor's behavior and biological features. Ask whether the current medicine is being continued for hormone control, cancer control or both.

Somatostatin-receptor imaging can also help assess whether receptor-targeted treatment is plausible. The team should explain the uptake pattern and whether the clinically important lesions show the relevant target. A receptor scan and a standard CT or MRI answer different questions and are often reviewed together.

Sources and references: [1]

Targeted medicines and chemotherapy

Everolimus and sunitinib are established medicines considered for advanced pancreatic NETs. Temozolomide-based chemotherapy is another pathway, particularly when the team needs tumor shrinkage or is concerned about the pace of growth. The choice includes prior treatment and how urgently a response is needed.

Cabozantinib received US FDA approval in March 2025 for previously treated, unresectable locally advanced or metastatic, well-differentiated pancreatic NETs in adults and patients aged 12 years or older. For a Shanghai plan, ask the specialist to check the current Chinese indication and prescribing route, then explain how the medicine compares with the other options that fit your treatment history.

Sources and references: [1] [2]

What a PRRT assessment needs

Peptide receptor radionuclide therapy, or PRRT, delivers radiation through a molecule that attaches to somatostatin receptors. It is a specialist option for selected receptor-positive disease. Kidney function, bone-marrow reserve, prior treatment and the distribution of receptor uptake influence the assessment.

Ask which radiopharmaceutical is proposed, why it fits the scan findings and how blood tests and radiation-safety instructions will be handled. A treatment-center review should address travel and follow-up as well as the treatment sessions. Confirm that the proposed center provides the particular PRRT treatment and can arrange the required monitoring.

Sources and references: [1] [4]

When local liver treatment is worth discussing

If liver deposits are causing the main symptoms or threaten liver function, a multidisciplinary team may consider surgery, ablation or an arterial treatment in selected patients. The volume and distribution of liver disease, tumor behavior elsewhere and general health shape that decision.

Local treatment has a defined task. Ask whether it is intended to remove limited disease, reduce hormone symptoms or control a dominant growing deposit. A plan for monitoring the rest of the disease should accompany it, including when another systemic treatment would be introduced.

Sources and references: [1]

Compare risks and monitoring before choosing a sequence

Targeted medicines can require close monitoring and dose changes. Chemotherapy can affect blood counts and cause nausea or fatigue; radionuclide treatment requires particular attention to kidney and marrow function. The team should relate these risks to your existing health problems and earlier side effects.

Keep a short record of weight, energy, bowel symptoms and any hormone-related episodes. Bring it to follow-up alongside the scan results. If control of symptoms and control of tumor size move in different directions, both deserve attention when deciding whether to continue or change treatment.

Sources and references: [1] [3] [2] [4]

Preparing a NET-focused consultation in Shanghai

Fudan University Shanghai Cancer Center's pancreatic tumor service treats neuroendocrine tumors. Its hospital profile and our pancreatic NET resource are starting points for a focused inquiry.

EastMedGo can help organize your pathology, Ki-67 result, scan history and previous medicines for consultation coordination. Tell us through contact whether the immediate concern is progression, hormone symptoms or a proposed PRRT course. We can help clarify which specialist review is needed and the practical arrangements before travel.

Sources and references: [5]

Common questions